Annovis Bio Inc (ANVS) Share Price

I find this CEO to be a person who faces shareholders full on; very impressive! Hopefully, July 2nd after the close she will address the actual timeline on the upcoming presentation (July 28th to August 1st)....7 minutes only or 45 minutes as mentioned by Maria.

Annovis Bio Files Patent for New Composition of Matter for Buntanetap
MALVERN, Pa.

June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.
This patent covers novel crystalline forms of buntanetap and their use for treating and/or preventing various neurodegenerative conditions. Crystalline forms offer significant advantages over less structured forms, including better solubility and stability. The most stable crystal form of buntanetap (CAS# 3032752-92-1) has been selected as the new lead compound for animal bridge studies and for developing a manufacturing process. The bridge studies were submitted to the FDA and will be discussed in July. The goal is to continue development of our drug and file the NDA with the new crystal form.
“The invention of a new solid form of our drug, buntanetap, and the subsequent patent filing represent groundbreaking milestones for our company. This achievement will allow us not only to continue advancing our pipeline, but also to enhance the drug's properties, ultimately providing greater benefits to our patients,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis.
A composition of matter patent comes with protection for the new buntanetap crystalline form and all its uses for a 20-year term.  The composition of matter patent is the single most important patent for any pharmaceutical company developing a new drug because it provides adequate runway to develop a drug and bring it to market.

Wondering if the results are good or bad.

What’s the consensus???

Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data

MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.

Investor Call Details:
Date and Time: July 2, 2024, 4:30pm ET.
Register Today: Webcast Registration
Topics to Be Covered:

Recent advancements in the development of Buntanetap.

Strategic plans for upcoming clinical trials.
Overview of the company’s progress and future direction.

Register Today: Investors and interested parties are encouraged to register for the webcast in advance. To register, please visit Webcast Registration and complete the registration form.

I am, but watching from the sidelines in case PD are a repeat of AD (as far as market reaction).

Murocman

Anyone here waiting for PD results later this month? A repeat of AD?

Its really hard to say, Im not familiar with the drugs MOA as I am say with Anavex’s drug. Perhaps others can comment.

In your opinion do you think this will repeat for PD results as well?

What a well said explanation of how they tried to screw up your clinical dataset…
I don’t think they planned on Maria playing Sherlock and putting Humpty Dumpty back together again.
Screw u big Pharma and blackhearts..
You suck.

This drug is a miracle of many to come

https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm

Looks like the CEO is trying everything and anything to stave off her Ouster. I believe in my opinion that their is huge some very big demand for her Ouster as CEO of this company after the recent trial PR and her PR’s from last year…..

I think the “market” wants those registered shares first. Dont want to use that lawsuit tool just yet until they extract as much as they can. Its a long road to commercialization with the next cycle in the “fair and balanced market” being to sell into the next pump.

ANVS will need to raise a lot of money for another phase 3. Many CEO’s and boards cut their losses, grab all their free shares and partner allowing the new partner to take over the final trial design and commercialization. This could be the just of whats playing out as we speak.

Wondering when we see all the Class Action notifications against
Dr. Maria L. Maccecchini and her incessant misinformation campaign from last year???

They almost got my 5.51s
Had sell in at 5.45

I keep raising the sell as it goes up

Shorts closing out today.

Looks like they are comin for your $5.51 shares.

OAN 2 million share registration at $5 isnt even goong to keep the doors open let alone pay for another ph 3. My guess is when the larger whales get what they want the price will go up. Maybe these 2 million are an “appetizer”.

Wednesday through Monday is the way of the biotech raiders. Great timing…, I say no, its a crafty game of shock and awe for the thieves. A transfer of wealth if you will by a band of greedy misfits. Any stumble, I mean ANY in the way they release their results and the company’s shareholders get max pain. Looks like they want those 2 million shares the CEO recently filed for dirt cheap. It happens to the best and the worst of them.

But t give healthy babies dangerous modified rna jabs..
Are you done with fda?
Join a general health phenomenal
phototherapy..
It’s a miracle..IMO..
Maybe you just stay healthy theough copper peptide activation..

Not a drug
Not a medicine

I think it’s a miracle..

Join us.. on a different path..
Thisisitinfo.com
Facebook.com/kingdomsevolution

The thugs run the financial markets

This annovis drug should already be available for the death sentenced demntia sufferers.. sorry it’s not.. we are betrayed by a corrupted system

Ouch. I barely missed it his one. I was thinking of dipping a toe recently in the $8-$10 range and glad I didnt chase it on their financing announcement. In hindsight it seems a bit smarmy on the surface announcing a financing round a day or two before releasing data when management knew how the market was going to react. Its an evil necessity but financing young biotechs is as brutal as it gets.

With a second phase 3 needed this company is in for a really long haul.

Good day here for me, in 5.51 and climbing..8.26 right now

The trial missed on_both primary endpoints: ADAS-CGIC and ADAS-ADL.

Great news in a needed therapy while shorts work to destroy the company.

5.51

where is bottom?

5-minute halts followed by 30-second trading windows.
Makes for an interesting L2 queue.

thats called shareholders selling into bad news with a low float reason for volatility halts

They missed endpoint ? Thats not good ->


Annovis Bio Shares Sink After Buntanetap Study Misses Endpoint
Mentioned: ANVS
By Dean Seal

Shares of Annovis Bio plummeted after the phase 2/3 study of its drug candidate buntanetap as a treatment for Alzheimer's disease missed a primary endpoint.

The stock was down 59% at $7.32 on heavy volume, with several pauses for volatility. Shares were trading around $14.57 a year ago and have swung between a high of $22.49 and a low of $5.42 in the past 12 months.

The clinical-stage drug-platform company said Monday that the phase 2/3 trial showed buntanetap producing a significantly higher rate of improvement in cognition assessment scores at each treatment dose relative to a placebo.

But another endpoint in the study, examining the drug's impact based on an assessment called Clinician's Global Impression of Change, was not met, with no statistically significant difference observed across all dosing groups of patients compared with a placebo group.

Annovis said the assessment is more subjective, allowing for a greater placebo effect as patients and caregivers were likely hopeful for a change.

The company said it plans to conduct a phase 3 study to confirm and expand its findings in an 18-month disease-modifying trial.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

April 29, 2024 11:18 ET (15:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.

Looks like the MM’s are trying to shake out all those Stop Losses and reset the 52 week low at the same time. Criminal…

Out of 325 patients who completed the Phase II/III trial, 202 had a ratio of pTau217/tTau≥4.2% that indicates AD.

In my honest opinion, MM’s and those who are short (over 17% of float is shorted legally- who knows how many illegal/naked shares are shorted) were not expecting this news today.

No. The news was stellar but the MM’s are doing what they do best.

The ground you mean ? Bad news

9$

Hey Annovis, ... Next time, Compose the 8K BEFORE the halt.

Wonder what it opens back up at after the Halt.

To the MOON!!!!!!!

Halted T1 news pending.
https://www.nasdaqtrader.com/trader.aspx?id=TradeHalts#

Probably the best financing agreement I have seen on one of these alternative AD plays. Seemingly shows a lot of confidence in the upcoming results.

Fantastic move today.

The 8K announces an ELOC. "Equity Line of Credit"

8K
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001477845/000110465924052471/tm2412796d1_8k.htm

REGISTRATION RIGHTS AGREEMENT
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001477845/000110465924052471/tm2412796d1_8k.htm

COMMON STOCK PURCHASE AGREEMENT
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001477845/000110465924052471/tm2412796d1_8k.htm

I’m guessing this from the last PR failed or at least they should be announcing in the next 5 business days……


“The AD Phase II/III study was completed in February, and we announced that we cleaned the data to our satisfaction and will release top-line efficacy results in April”.

Any ideas why ANVS sp is down so much the last few days. I’ve seen no news, good or bad?

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

Peer reviewed article came out.

Maybe less than 2 weeks to go for the data to come, at the most 3 weeks, but it could also be next week.

"This month, the FDA issued guidance on developing drug treatments for early Alzheimer's disease, a must-read for all $ANVS investors. The FDA emphasizes significant clinical improvement as the key outcome. If trials show clinical improvement backed by biomarker data, companies may seek traditional approval. If only biomarkers show improvement and clinical benefits need more time to manifest, accelerated approval might be pursued, contingent on further trials. This aligns with $ANVS's strategy of prioritizing clinical improvement as the primary endpoint in its PD and AD trials. I'm optimistic about the potential for approval based on upcoming PD and/or AD trial outcomes. While longer trials are anticipated, impressive results could pave the way for submitting approval applications almost immediately post-trial. The company has stated that they will meet with the FDA shortly after the trials are read out. It will be very interesting to see if they're given the ok to apply..."

Looks like maybe some small news tomorrow, damn on Good Friday, really? C'mon now.